Atossa Therapeutics appoints breast cancer specialist Dr. Tessa Cigler to board

ATOSSA THERAPEUTICS, INC.

Dr. Cigler is a medical oncologist and clinical investigator at Weill Cornell Breast Center.
She will serve as Class II director until 2026 annual meeting and on Nominating and Governance Committee.
Appointment effective immediately; compensation follows standard non-employee director terms.
Company's (Z)-endoxifen program has four Phase 2 trials; two expected to readout in H2 2024.
Dr. Cigler holds M.D. from Duke, M.P.H. from Harvard, and extensive breast cancer clinical trial experience.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Tessa Cigler

Class II Director

ATOS · ATOSSA THERAPEUTICS, INC.

Effective: 2024-03-09
Filed: March 12, 2024, 7:59 PM ET

On March 9, 2024, the Board of Directors (the “Board”) of Atossa Therapeutics, Inc. (the “Company”) expanded its size and appointed Dr. Tessa Cigler, M.D., M.P.H. as a Class II director to hold office until the 2026 Annual Meeting of Stockholders and until her successor shall have been duly elected and qualified, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Tessa Cigler was appointed as Class II Director at ATOSSA THERAPEUTICS, INC..

Action: appointed
Role: Class II Director

Exact text from the filing

On March 9, 2024, the Board of Directors (the “Board”) of Atossa Therapeutics, Inc. (the “Company”) expanded its size and appointed Dr. Tessa Cigler, M.D., M.P.H. as a Class II director to hold office until the 2026 Annual Meeting of Stockholders and until her successor shall have been duly elected and qualified, effective immediately.

View on SEC.gov

ATOSSA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0000950170-24-029671

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.